Description
XL-228 is a third generation inhibitor of Abl that shows efficacy in a variety of cell lines, including those exhibiting T315I mutations. XL-228 displays anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for chronic myelogenous leukemia (CML).
|
|||||||||||||
Specifications | |||||||||||||
|
Shanghai HuicH Biotech Co.,Ltd.
上海惠诚生物2010年至今专注于食品检测方面的标准品,优势品牌系列:
药物: TRC LGC USP LKT Focus
植提标准品: Extrasynthese PhytoLab Chromadex CaroteNature
糖类: Elicityl TDB Ludger Megazyme Glycarbo
脂类: Nu-Chek Larodan Avanti Matreya
其他: TCI ERM Wako Jackson Cayman laysan
手机微信:17715331663 QQ:2303607288